debate: alk positive nsclc - front line therapy - crizotinib
Published 9 years ago • 1K plays • Length 13:28Download video MP4
Download video MP3
Similar videos
-
11:38
debate: alk positive nsclc - front line therapy - ceritinib
-
13:18
nsclc: how to handle alk resistance
-
33:52
keynote lecture: targeted therapies in lung cancer 2.0 – advances and promises
-
6:51
progression in alk nsclc after frontline therapy
-
3:57
lack of awareness of alk-positive lung cancer. a patient’s perspective.
-
10:06
똑똑한 암세포 잡는 표적항암제 총정리 - 연세암병원 종양내과 임선민 교수
-
1:15:42
alk 101 part 5: life after lorlatinib
-
10:06
debate: what is the optimal timing for egfr-targeted therapy? - favor frontline therapy
-
22:10
first and second generation alk inhibitors for the treatment of lung cancer
-
21:51
eml4/alk and ros-1: how do we sequence therapies
-
32:12
immunotherapy in non-small cell lung cancer (nsclc): front line therapy
-
1:05
what targeted therapies are used for people with the alk mutation?
-
7:02
crizotinib for alk-rearranged nsclc
-
18:41
expert perspectives: lung cancer
-
26:24
the therapeutic implications of eml4/alk, ros-1 and other actionable biomarkers
-
3:04
management of frontline alk nsclc: brigatinib vs. alectinib
-
1:17
dr. christina baik on alectinib versus crizotinib in alk-positive lung cancer
-
8:15
alex trial: frontline therapy for alk-rearranged nsclc
-
20:24
targeted treatment with egfr tkis: front line options
-
1:42
dr. velcheti on potential of alectinib in frontline alk-positive nsclc
-
1:17
dr. xia on the frontline treatment landscape of alk-positive nsclc